Olanzapine (Zyprexa, Zyprexa Zydis, or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of: schizophrenia on 1996-09-30 ; depressive episodes associated with bipolar disorder, as part of the Symbyax formulation, on 2003-12-24 ; acute manic episodes and maintenance treatment in bipolar disorder on 2004-01-14 . Off-label uses are listed below.

The olanzapine formulations are manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper expires in 2011.